Pacific Shuanglin Bio-pharmacy Co., Ltd. (SHE:000403)
11.71
+0.03 (0.26%)
May 8, 2026, 3:04 PM CST
SHE:000403 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 2,600 | 2,631 | 2,654 | 2,325 | 2,396 | 1,966 |
Other Revenue | 1.14 | 1.14 | 1.05 | 3.27 | 9.59 | 5.27 |
| 2,601 | 2,633 | 2,655 | 2,329 | 2,405 | 1,972 | |
Revenue Growth (YoY) | 0.28% | -0.83% | 14.00% | -3.18% | 21.98% | 87.80% |
Cost of Revenue | 1,572 | 1,544 | 1,352 | 1,130 | 1,151 | 1,064 |
Gross Profit | 1,028 | 1,089 | 1,303 | 1,199 | 1,254 | 907.93 |
Selling, General & Admin | 444.44 | 438.17 | 437.26 | 465.81 | 565.05 | 419 |
Research & Development | 56.13 | 55.92 | 55.18 | 79.69 | 75.36 | 35.63 |
Other Operating Expenses | 26.56 | 22.26 | 22.07 | 21.69 | 16.8 | 15.28 |
Operating Expenses | 539.77 | 525.12 | 509.9 | 565.15 | 666.86 | 477.73 |
Operating Income | 488.69 | 563.97 | 793.13 | 633.7 | 587.01 | 430.2 |
Interest Expense | -19.59 | -18.19 | -10.67 | -9.63 | -12.03 | -10.78 |
Interest & Investment Income | 59.39 | 63.52 | 78.01 | 75.08 | 68.22 | 62.3 |
Currency Exchange Gain (Loss) | 0.01 | 0.01 | 0.13 | -0.12 | 2.4 | -0.21 |
Other Non Operating Income (Expenses) | 3.51 | -0.3 | 0.03 | 0.64 | -2.23 | -3.44 |
EBT Excluding Unusual Items | 532.02 | 609.01 | 860.61 | 699.67 | 643.37 | 478.06 |
Impairment of Goodwill | -78.6 | -78.6 | - | - | - | -103.18 |
Gain (Loss) on Sale of Investments | 5.68 | 4.3 | 6.38 | -18.97 | 4.93 | 74.21 |
Gain (Loss) on Sale of Assets | 0.72 | 0.76 | -0.12 | -0.54 | 0.44 | 0.27 |
Asset Writedown | -17.86 | -17.86 | -3.46 | -1.29 | -3.59 | -0.49 |
Legal Settlements | - | - | - | - | - | -2.14 |
Other Unusual Items | -15.94 | -17.3 | -10.87 | 9.25 | 15.24 | 11.28 |
Pretax Income | 426.02 | 500.3 | 852.78 | 688.11 | 660.39 | 458.01 |
Income Tax Expense | 72.69 | 80.77 | 107.74 | 76.64 | 72.7 | 66.47 |
Earnings From Continuing Operations | 353.33 | 419.54 | 745.04 | 611.47 | 587.69 | 391.54 |
Minority Interest in Earnings | -0.18 | -0.27 | 0.28 | 0.64 | -0.56 | -0.48 |
Net Income | 353.15 | 419.27 | 745.32 | 612.11 | 587.13 | 391.06 |
Net Income to Common | 353.15 | 419.27 | 745.32 | 612.11 | 587.13 | 391.06 |
Net Income Growth | -50.43% | -43.75% | 21.76% | 4.25% | 50.14% | 110.29% |
Shares Outstanding (Basic) | 993 | 953 | 956 | 947 | 950 | 917 |
Shares Outstanding (Diluted) | 993 | 953 | 956 | 947 | 950 | 919 |
Shares Change (YoY) | 2.33% | -0.28% | 0.88% | -0.33% | 3.38% | 44.25% |
EPS (Basic) | 0.36 | 0.44 | 0.78 | 0.65 | 0.62 | 0.43 |
EPS (Diluted) | 0.36 | 0.44 | 0.78 | 0.65 | 0.62 | 0.43 |
EPS Growth | -51.56% | -43.59% | 20.71% | 4.60% | 45.23% | 45.78% |
Free Cash Flow | -544.84 | -549.39 | -198.92 | 301.74 | 145.58 | 82.06 |
Free Cash Flow Per Share | -0.55 | -0.58 | -0.21 | 0.32 | 0.15 | 0.09 |
Dividend Per Share | - | - | 0.385 | 0.154 | 0.062 | 0.043 |
Dividend Growth | - | - | 150.06% | 149.27% | 43.16% | - |
Gross Margin | 39.54% | 41.37% | 49.08% | 51.48% | 52.13% | 46.05% |
Operating Margin | 18.79% | 21.42% | 29.88% | 27.21% | 24.41% | 21.82% |
Profit Margin | 13.58% | 15.93% | 28.08% | 26.28% | 24.41% | 19.83% |
Free Cash Flow Margin | -20.95% | -20.87% | -7.49% | 12.96% | 6.05% | 4.16% |
EBITDA | 622.69 | 696.19 | 918.23 | 770.71 | 704.63 | 538.01 |
EBITDA Margin | 23.94% | 26.45% | 34.59% | 33.10% | 29.30% | 27.29% |
D&A For EBITDA | 133.99 | 132.22 | 125.1 | 137.02 | 117.62 | 107.82 |
EBIT | 488.69 | 563.97 | 793.13 | 633.7 | 587.01 | 430.2 |
EBIT Margin | 18.79% | 21.42% | 29.88% | 27.21% | 24.41% | 21.82% |
Effective Tax Rate | 17.06% | 16.14% | 12.63% | 11.14% | 11.01% | 14.51% |
Revenue as Reported | 2,601 | 2,633 | 2,655 | 2,329 | 2,405 | 1,972 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.